Regulatory Landscape for Addiction Treatments: Evolving FDA policies and congressional support for alternative endpoints in Substance Use Disorder trials directly impact the development and approval pathway for AD04.

Access to Capital / Investor Sentiment in Biotechnology: As a clinical-stage company without commercialized products, Adial Pharmaceuticals is highly reliant on successful fundraising rounds, partnerships, and overall investor appetite for speculative biotech ventures, which can be sensitive to broader economic conditions and interest rates.

Competition and Clinical Trial Success in Addiction Medicine: The company operates in a competitive therapeutic area. The success or failure of AD04's clinical trials and the emergence of competing therapies are critical to its future prospects.